Personalis, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; the filing is an annual report rather than a standalone quarterly filing. Personalis provides cancer genomic testing, sequencing and data-analysis services, including NeXT Platform products, and population whole-genome sequencing for the U.S. Department of Veterans Affairs Million Veteran Program.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $65.0 million | $85.5 million | Down 24% |
| Gross profit | $13.4 million | $31.7 million | Down 58% |
| Gross margin | 20.5% | 37.0% | Down 16.5 points |
| Loss from operations | $(115.5) million | $(65.4) million | Loss increased |
| Operating margin | (177.6)% | (76.4)% | Declined |
| Net loss | $(113.3) million | $(65.2) million | Loss increased 74% |
| Net loss per share | $(2.48) | $(1.49) | Worsened |
| Cash used in operations | $(70.2) million | $(70.8) million | Broadly unchanged |
| Capital expenditures | $49.9 million | $11.1 million | Up substantially |
| Cash and short-term investments | $167.7 million | $287.1 million | Down $119.4 million |
| Total debt | $2.6 million | $3.5 million | Down $0.9 million |
Revenue mix shifted materially. Pharma tests and services generated $29.6 million, enterprise sales generated $26.6 million, population sequencing generated $8.4 million, and other revenue generated $0.4 million. Enterprise revenue increased 204%, primarily from higher Natera sample volumes, while population sequencing revenue declined 82% because of lower VA MVP task orders.
Research and development expense increased 32% to $64.9 million, and selling, general and administrative expense increased 34% to $64.0 million. Stock-based compensation was $19.4 million. Working capital was $166.6 million at year-end. Operating lease liabilities totaled $46.4 million, and future noncancelable operating lease payments totaled $83.8 million.
Material changes versus the prior comparable period
- Total revenue fell $20.4 million, primarily because VA MVP population sequencing revenue declined $37.2 million.
- Enterprise sales rose $17.9 million as Natera sample volumes increased more than 300%, although volume-based pricing reduced average selling prices.
- Gross margin contracted due to lower revenue, fixed laboratory and facility costs, and investments in enterprise and pharmaceutical testing capabilities.
- R&D and SG&A increased as Personalis expanded clinical offerings, validation studies, diagnostics personnel, commercial operations and its Fremont facility.
- Personalis moved its corporate headquarters to a 100,000-square-foot Fremont facility under a lease extending to 2036; laboratory operations remained in Menlo Park at year-end.
- Customer concentration increased: Natera represented 41% of revenue, VA MVP 13%, and Merck 11%. The five largest customers represented 76% of revenue.
- John West retired as CEO effective December 31, 2022. Aaron Tachibana became interim CEO while remaining CFO, and Christopher Hall became President.
Outlook, commentary, risks and unusual items
- Management expects existing cash, cash equivalents and short-term investments, together with anticipated operating cash receipts, to fund requirements for at least the next 12 months, but states that additional capital may be needed. An unused $100 million at-the-market equity program was available at year-end.
- Management expects 2023 capital expenditures of approximately $4 million to $6 million annually for 2023 through 2025, substantially below 2022 as the Fremont build-out is largely complete.
- Personalis plans to focus on immunotherapy monitoring, breast cancer and lung cancer, while building clinical evidence for NeXT Personal and expanding NeXT Dx. No formal revenue or earnings guidance is provided.
- In January 2023, the company approved a workforce reduction of approximately 30%, with expected charges of about $3 million, mostly in the first quarter of 2023.
- Personalis decided to close its China operations in 2023 and expects one-time charges, including noncash impairments, not exceeding $1.5 million.
- A January 2023 electrical failure at the Fremont facility required backup generators and disrupted office and facility operations. Management expected the landlord to reimburse related costs, but reimbursement was not guaranteed.
- Personalis sued Foresight Diagnostics for patent infringement. Foresight filed counterclaims and four inter partes review petitions; the district court stayed the litigation pending resolution of the patent proceedings. The financial impact cannot be estimated.
- Key risks include continued losses, cash burn and potential dilution; dependence on Natera and VA MVP; uncertain reimbursement and regulatory treatment of laboratory-developed tests; reliance on Illumina as a key supplier; execution risks in relocating the laboratory; cybersecurity and data privacy exposure; competition; and intellectual-property litigation.
Investor verification checklist
- Confirm the pace of cash usage and whether $167.7 million of year-end liquidity remains sufficient after workforce reductions, Fremont costs, lease obligations and China closure costs.
- Track Natera sample volumes, pricing and contract terms, given Natera's 41% revenue contribution and nonexclusive arrangement.
- Verify VA MVP renewals, task-order values and sample deliveries, including the $9.1 million of the 2022 task order expected to be recognized in 2023.
- Assess whether NeXT Personal and NeXT Dx achieve clinical validation, physician adoption and reimbursement.
- Monitor the Fremont laboratory transition, electrical remediation, licensing and CLIA/CAP certification transfer.
- Follow the Foresight patent litigation and inter partes review proceedings for potential legal costs, injunctions or technology restrictions.
- Review dilution risk from the $100 million ATM facility, equity awards and 9.1 million potentially dilutive shares excluded from 2022 diluted EPS.